A number of other brokerages also recently issued reports on RGNX. Evercore ISI upgraded shares of Regenxbio from an in-line rating to an outperform rating and set a $51.25 price target for the company in a research note on Monday, February 25th. Zacks Investment Research downgraded shares of Regenxbio from a buy rating to a hold rating in a research report on Saturday, February 23rd. Barclays boosted their price objective on shares of Regenxbio from $83.00 to $88.00 and gave the stock an overweight rating in a research report on Tuesday, December 18th. Chardan Capital restated a buy rating and set a $127.50 price objective on shares of Regenxbio in a research report on Friday, January 4th. Finally, Morgan Stanley reduced their price objective on shares of Regenxbio from $93.00 to $85.00 and set an overweight rating for the company in a research report on Wednesday, December 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Regenxbio has an average rating of Buy and an average price target of $77.97.
Shares of Regenxbio stock opened at $53.67 on Tuesday. Regenxbio has a 52-week low of $35.65 and a 52-week high of $85.10. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.94 billion, a P/E ratio of 22.55 and a beta of 0.47.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.43. Regenxbio had a net margin of 45.74% and a return on equity of 22.33%. On average, equities research analysts anticipate that Regenxbio will post -3.22 EPS for the current fiscal year.
In related news, SVP Curran Simpson sold 5,300 shares of the company’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $54.05, for a total value of $286,465.00. Following the completion of the sale, the senior vice president now owns 44,800 shares in the company, valued at approximately $2,421,440. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Vittal Vasista sold 3,068 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $60.01, for a total transaction of $184,110.68. Following the completion of the sale, the chief financial officer now owns 239,215 shares of the company’s stock, valued at approximately $14,355,292.15. The disclosure for this sale can be found here. Insiders have sold a total of 92,200 shares of company stock valued at $4,860,482 in the last 90 days. Insiders own 16.90% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Los Angeles Capital Management & Equity Research Inc. raised its position in Regenxbio by 2.1% in the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,192 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 225 shares during the last quarter. Municipal Employees Retirement System of Michigan purchased a new stake in Regenxbio in the 4th quarter valued at $357,000. Vanguard Group Inc. raised its position in Regenxbio by 51.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,805,969 shares of the biotechnology company’s stock valued at $211,851,000 after purchasing an additional 947,671 shares during the last quarter. MetLife Investment Advisors LLC raised its position in Regenxbio by 66.9% in the 3rd quarter. MetLife Investment Advisors LLC now owns 22,065 shares of the biotechnology company’s stock valued at $1,666,000 after purchasing an additional 8,848 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in Regenxbio by 0.9% in the 4th quarter. Principal Financial Group Inc. now owns 249,625 shares of the biotechnology company’s stock valued at $10,472,000 after purchasing an additional 2,124 shares during the last quarter. Hedge funds and other institutional investors own 82.18% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.